A major trial has demonstrated that fulvestrant–palbociclib combination therapy may prolong survival and delay the need for chemotherapy in women with advanced breast cancer.
Browsing: breast cancer
A combination of the targeted drug vistusertib with paclitaxel chemotherapy has shown promise in an early clinical trial, in patients with ovarian or lung cancer for whom all other treatments had failed.
Find out exclusive insights about the career of V. Craig Jordan who is considered the “father of tamoxifen” as well as details of the research areas he and his mentee Balkees Abderrahman are investigating.
Student aims to 3D print breast cancer tumors in an attempt to provide faster and more effective treatment for the disease.
A Phase 1b clinical trial investigating tucatinib combined with ado-trastuzumab emtansine in advanced ERBB2/HER2-positive metastatic breast cancer has yielded encouraging results.
The TAILORx study has demonstrated that most women with a specific early-stage breast cancer and midrange score on the Oncotype DX® test do not need chemotherapy after surgery.
In a medical breakthrough, a new approach to immunotherapy has led to complete regression of breast cancer in a patient unresponsive to all other treatments.
Today’s plenary session has revealed some of the biggest stories from ASCO; find out further details of CARMENA, KEYNOTE-042 and TAILORx plus much more by clicking the link below.
The Phase III TAILORx clinical trial results indicate that most women with a specific early-stage breast cancer and midrange score on a gene expression assay do not need chemotherapy after surgery.
Results from a Phase lll clinical trial demonstrate the success of a new targeted medicine, taselisib, in treating advanced breast cancer.